Development of selective probe compounds to help unlock cancer's secrets

The development of targeted therapies is a critical cornerstone in the fight against Cancer. A key part of this process is the development of selective cell permeable probe compounds which can be used to assess a target's role in relevant cellular models. As part of our drug discovery work, Cancer Research Technology Discovery Laboratories (CRT-DL) has developed a number of well characterised probe compounds against potential cancer targets which are available to the wider academic community. We will describe aspects of the development and characterisation of several probes including ones targeting glycolysis, phosphatidylinositol signalling and atypical Protein Kinase C. CRT-DL will be making these assets available to cancer researchers to advance the science in these areas of biology.

Poster presented by Martin Swarbrick at the NCRI Cancer Coference 2015 (Liverpool, UK)

For reprints please contact: Enquiries@crtdiscoverylabs.com